Introduction
The endothelium plays an important role in the regulation of vasomotor tone through a balanced release of various vasodilators and vasoconstrictors (Furchgott and Vanhoutte, 1989; Vanhoutte et al., 2009) . In hypertension, endothelial dysfunction with inappropriate release of vasoactive mediators is observed (Rubanyi 1993; Vanhoutte et al., 2009) . A reduced production of endothelium-derived vasodilators, in particular nitric oxide (NO) and an increased production of endothelium-derived vasoconstrictor prostanoids have been reported in many studies (Lüscher, 1990; Vanhoutte et al., 2005) .
Endothelium-dependent contractions in the rat aorta are augmented in the presence of L-NAME (N ω -nitro-L-arginine methyl ester), an analogue of L-arginine which inhibits nitric oxide synthases (NOS; Auch-Schwelk et al., 1992; Tang et al., 2005a Tang et al., , 2005b . Indeed, inhibition of NOS by L-NAME results in an increased production of endothelium-derived contracting factors (EDCF) which are vasoconstrictor prostanoids produced from arachidonic acid by the enzyme cyclooxygenase (COX). EDCF in turn activate thromboxane-prostanoid (TP) receptors on vascular smooth muscle, resulting in vasoconstriction (Auch-Schwelk et al., 1990 and 1992; Yang et al., 2004a; Tang et al., 2005a) .
EDCF-mediated contractions are augmented in arteries of spontaneously hypertensive rats (SHR; Lüscher and Vanhoutte, 1986; Yang et al., 2004a; Tang et al., 2005a) . Acute and chronic This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from JPET #167098 8 inhibition of NOS causes hypertension in animals (Rees et al., 1989) . The present study was designed to investigate whether or not hypertension resulting from the chronic inhibition of NOS by L-NAME modulates EDCF-mediated contractions of the rat aorta. When this appeared to be the case, the molecular mechanism involved was determined.
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Materials and Methods
The experimental procedures used in the present study followed the National Institutes of with a 12:12-h light-dark cycle and were randomly divided into two groups: the treated group was given the NOS inhibitor, L-NAME (60 mg/kg/day by gavage) and the control group was given vehicle (distilled water; 1 ml/kg/day, by gavage). The rats were fed a normal chow diet and had free access to tap water. After six weeks of treatment, rats were anesthetized with pentobarbitone sodium (70 mg/ml/kg, given intraperitoneally) and their arterial blood pressure was measured through a cannula inserted into one of the carotid arteries. Arterial blood samples were collected for measuring the plasma concentration of nitrate (the metabolite of NO) detected as the amount of nitrite in the plasma.
Thoracic aortae were dissected free and placed into a modified Krebs-Ringer solution (pH 7.4) containing 118 mM NaCl, 4.7 mM KCl, 2.5 mM JPET #167098 10 25 mM NaHCO 3 , and 11.1 mM glucose (control solution). The aortae were freed of connective tissue and fat, and then cut into rings of approximately 3 mm length. Care was taken during the dissecting procedure to protect the endothelium from inadvertent damage. In some preparations, the endothelium was removed by perfusion with 1 ml Triton X-100 solution (0.1%) for 30 seconds prior to cutting the rings. The presence or absence of relaxation to 2-(acetyloxy)-N,N,N-trimethylethanaminium chloride (acetylcholine; 3 μ M) during a contraction
was used to verify endothelial integrity or functional removal respectively.
Isometric Tension Recording. Aortic rings were suspended by means of two L-shape stainless-steel wires inserted into the lumen in a organ chamber containing control solution kept at 37°C, and continuously bubbled with a gas mixture of 95% O 2 -5% CO 2. They were allowed to equilibrate for one and half hour. The baseline tension was 2.5 g. Changes in isometric tension were recorded using a force transducer (MLT0201, ADInstruments Pty Ltd., NSW, Australia)
coupled to an octal bridge amplifier and a data acquisition system (ML119 and Powerlab model ML785, respectively, ADInstruments Pty Ltd., NSW, Australia were used in the assay (Futaki et al., 1994; Smith et al., 1998) .
Prostanoids Immunoassay. The levels of 6-keto prostaglandin F 1α (6-keto PGF 1α , stable metabolite of prostacyclin), PGF 2α and thromboxane B 2 (stable metabolite of thromboxane A 2 ) released into the buffer in the organ chamber by A23187-stimulated aortic rings were measured using enzyme immunoassay kits (Caymen Chemical, Ann Arbor, MI). Briefly, the buffer in the organ chamber were collected at the maximal level of aortic contraction induced by A23187 (10 μ M), as described in "isometric tension recording", and stored at -80 o C until use (Gluais et al, 2005) . The buffer was assayed after different dilution (100× for 6-keto PGF 1α , 10× for PGF 2α , and 1× for thromboxane B 2 ) in triplicates and performed according to the manufacturer's instructions.
Western Blotting. The protein expressions of endothelial NOS (eNOS), COX-1, COX-2 and TP receptors were analyzed by Western blotting. Aortic rings with and without endothelium from L-NAME treated and control rats were homogenized in a lysis buffer composed of leupetin (1 μ g/ml), aprotonin (5 μ g/ml), phenylmethylsulfonyl fluoride Drugs. Calcium ionophore A23187, L-NAME and NS-398 were purchased from Sigma Chemical Company (St Louis, MO, USA). Prostaglandin E 2 (PGE 2 ) and SC-560 were purchased from Cayman Chemical. The organic solvent dimethyl sulfoxide was purchased from Merck 
Results
Body Weight and Arterial Blood Pressure. The body weight of the animals subjected to L-NAME treatment (60 mg/kg/day) was not significantly different from that of the controls until day 35; after this time it decreased progressively (Supplementary Figure) . At the end of the treatment, both the diastolic and systolic arterial pressures were significantly higher in the chronic L-NAME treated rats than control rats (Supplementary Figure) .
Endothelium-Dependent Relaxations. After six weeks of L-NAME treatment, endothelium-dependent relaxations produced by the calcium ionophore A23187 in aortic ring were impaired significantly compared to those from control rats (Fig. 1A) . The presence of L-arginine (1 mM, 30 minutes preincubation) improved the impaired relaxation of rings from L-NAME treated rats, but not to the control level (Fig. 1A) . Endothelium-independent relaxations to the NO + donor sodium nitroprusside were comparable in aortae of L-NAME treated and control rats (Fig. 1B) .
Incubation of aortic rings with SC-560 (1 μ M), NS-398 (10 μ M) or S18886 (100 nM), did not significantly modify A23187-induced relaxations in control aortae ( Fig. 2A) . In rings from chronic L-NAME treated rats, the presence of NS-398 and S18886 significantly improved the A23187-induced relaxation whereas SC-560 failed to affect the response (Fig. 2B ).
Endothelium-Dependent Contractions.
In the presence of L-NAME (100
This article has not been copyedited and formatted. The final version may differ from this version. produced endothelium-dependent contractions in aortae of control and chronic L-NAME treated rats. The contractions to A23187 were significantly greater in aortic rings from L-NAME treated rats than from control rats (Fig. 3A) . A23187 produced minimal contractions in the absence of endothelium.
In the aortae of both of the treated and control rats, the contractions induced by A23187
were not affected by the presence of SC-560 (1 μ M). NS-398 (10 μ M) significantly inhibited endothelium-dependent contractions induced by A23187 in aortae of L-NAME treated rats. The TP receptor antagonist, S18886 (100 nM) abolished the endothelium-dependent contractions to the calcium ionophore (Fig. 3B ).
The concentration-response curve to U46619 was shifted to the left in aortic rings from L-NAME rats compared to control rings (Fig. 4) .
Plasma Nitrate, COX Activity and Prostanoids Release. After six weeks of L-NAME treatment, the plasma nitrate level (an indication of NO level), which was determined as the amount of nitrite in Griess assay, was significantly lower than that in the controls (Fig. 5A ).
There was a small but significant elevation in COX-1 activity after chronic L-NAME treatment.
The COX-2 activity was negligible in the aorta of control rats but was increased significantly in L-NAME treated rats (Fig. 5B) . The releases of 6-keto PGF 1α , PGF 2α and thromboxane B 2 induced by A23187 were significantly increased after chronic administration of L-NAME This article has not been copyedited and formatted. The final version may differ from this version. compared to that in arteries of the vehicle-treated animals. The increase in production of the metabolites of arachidonic acid was abrogated by the COX-2 inhibitor NS-398 but not by the COX-1 inhibitor SC-560 (Fig. 5C ).
Protein Expression. The eNOS expression was reduced significantly in aortae from rats after chronic L-NAME treatment compared to the controls (Fig. 6A ). Both COX-1 and COX-2 expressions were significantly higher in aortae from L-NAME treated rats than in control preparation. The protein expressions of COX-1 and COX-2 were reduced after the removal of the endothelium (Figs. 6B and 6C, respectively). The expression of TP receptors was comparable in aortae from the treated and control rats (Fig. 6D ).
Immunohistochemical analysis demonstrated that COX-1 and COX-2 were mainly located in the endothelium (Figs. 7A and 7B ). The presence of COX-1 and COX-2 were higher in the aortae after the rats were chronically treated with L-NAME (Figs. 7A and 7B). Consistent with the results of Western immunoblotting, the eNOS expression in aorta from rats chronically treated with L-NAME was significantly reduced compared with the control group (Fig. 7C ).
This article has not been copyedited and formatted. The final version may differ from this version. We observed that long-term inhibition of eNOS resulted in impairment of vascular relaxation. The inhibitory effect of L-NAME on NO production and vascular relaxation can be reversed by L-arginine, a substrate of NOS which can compete with L-NAME on eNOS (Knowles and Moncada, 1994) . In the present study, L-arginine, failed to fully restore the relaxation to the control level, indicating that the decrease in relaxation is not solely due to L-NAME remaining in the aorta after the chronic treatment. We also observed that the plasma NO level as determined by measuring the metabolite of NO and the aortic eNOS expression are reduced in rats chronically treated with L-NAME. These results are consistent with a chronic depression of the ability of the endothelial cells to release NO (Lüscher and Vanhoutte, 1990) .
When the production of NO release from the endothelial cell is decreased, endothelium-dependent contractions are augmented, and endothelial dysfunction becomes established (Auch-Schwelk et al., 1992; Vanhoutte, 2003; Yang et al., 2004b) .
Endothelium-mediated contractions are dependent on the activity of endothelial cyclooxygenase. Two isoforms of COX have been identified and both of these heme-proteins have an equal chance to oxidize arachidonic acid into prostaglandins (Garavito and DeWitt, 1999) . In the SHR and WKY aorta, COX-2 is a highly inducible enzyme, whereas COX-1 is , 1995; Yang at al., 2003 Yang at al., , 2004a Tang et al., 2005a) , the present data suggests that COX-2 is involved in the production of EDCF in rats chronically treated with L-NAME. The different in the subtype of COX involved may be related to the strain or species of the animal used or to the underlying pathophysiology that leads to the development of endothelium-dependent contractions. Indeed, aging-induced endothelium-dependent contractions in Wistar rats, Sprague Dawley rats and hamster are related to increased expressions and activity of COX-2 (Heymes et al., 2000; Shi et al., 2008; Wong et al., 2009 ).
The present results confirm that A23187 produces concentration-dependent and endothelium-dependent contractions in the rat aorta (Auch-Schwelk et al., 1992; Yang et al., 2004a; Gluais et al., 2006) . These contractions are potentiated in aortae of rats treated chronically with L-NAME, as they are in the aorta of the SHR (Lüscher and Vanhoutte 1986; Yang et al., 2004a; Gluais et al., 2005) In the present studies, Western blot analysis showed that both COX-1 and COX-2 expression were increased in rings with endothelium after chronic L-NAME treatment. However, the over-expression of COX-2 after rats treatment with L-NAME was to a much greater extent (about five-fold compared with the control group) compared to that of COX-1. The comparison of aortae with and without endothelium allows the conclusion that COX-2 protein expression is localized mainly in the endothelium. This endothelial localization of the upregulated COX-2 was appears to represent the major isoform of the enzyme for the augmented generation of EDCF in aortae of rats subjected to the chronic administration of L-NAME. The comparison of total and individual COX activities in the aortae before and after L-NAME administration confirmed the predominant role of COX-2, as there is a more obvious increase in COX-2 and total COX activity than in COX-1. The importance of the augmented COX-2 expression and activity in the impaired relaxation and enhanced contraction was further established by the ability of a selective COX-2 inhibitor but not of a COX-1 inhibitor to reverse the changes in vascular responses observed in arteries from L-NAME treated rats.
While COX-2 expression increases under a number of pathophysiological conditions (Heymes et al., 2000; LaPointe et al., 2004; Shi et al., 2008) , an increased COX-1 expression may compensate the adverse effects caused by COX-2 (Moncada 1982; Deeb et al., 2008) .
COX-2 mediated vasoconstriction is augmented in hypertension (Alvarez et al., 2005) . In the present study, COX-1 blockade did not affect the A23187-induced EDCF-mediated contractions, and did not improve the blunted A23187-induced relaxation after chronic NOS inhibition. By contrast, the presence of a COX-2 inhibitor in the organ chamber blocked the EDCF-mediated responses and attenuated the impaired relaxation in aortae from rats with chronic L-NAME treatment suggesting that COX-2 is the isoform responsible for the EDCF production in this This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #167098 23 experimental model, as it is in the aged hamster aorta (Wong et al., 2009 ). This conclusion is also validated by the changes in the production of the three major vasoconstrictors namely prostacyclin, PGF 2α and thromboxane A 2 . Indeed, the augmented levels of prostaglandin end-products (6-keto PGF 1α for prostacyclin and thromboxane B 2 for thromboxane A 2 ) and PGF 2α in the presence of A23187 after chronic inhibition of eNOS were decreased by acute incubation with a selective COX-2 inhibitor but not by a selective COX-1 inhibitor. Although prostacyclin is generally regarded as a powerful vasodilator (Moncada 1982; Deeb et al., 2008) , it has been established for many years that prostacyclin causes no relaxations in arteries of hypertensive or aged rats (e.g. Levy et al., 1980; Gluais et al., 2005) . As such, all of the prostaglandin end-products produced by COX-2 may contribute to the endothelium-dependent contractions in the aorta of chronic L-NAME-induced hypertensive rats.
In hypertensive rat aorta, endothelium-dependent contractions ultimately are mediated by activating receptors on the vascular smooth muscle cells recognized as TP receptors, in view of the ability of TP receptor antagonist to abolish these responses (Auch-Schwelk et al., 1990; Yang et al., 2003) . The results of the present experiments indicate that the expression of TP receptors at the protein level is not altered by the chronic L-NAME administration indicating that changes in their density is not a contributing mechanism in the augmented endothelium-dependent preparations. This suggests an increased sensitivity of the TP receptors of the smooth muscle cells of chronically L-NAME treated rats, consistent with the augmented contractions to endoperoxides observed in the SHR aorta study (Ge et al., 1995) .
In addition to the conduit artery studied here, resistance blood vessels, such as small coronary arteries and mesenteric arteries, also release cyclooxygenase-derived endothelium-dependent contracting factor in experimental hypertensive animals Kähönen et al., 1998; García-Redondo et al., 2009) . The contribution of EDCF to endothelial dysfunction in hypertension is also demonstrated in human studies, as endothelium-dependent vasodilatations in human hypertensive patients, but not in normotensive subjects, are improved by the inhibitor of COX, indomethacin (Taddei et al., 1993 , Taddei et al., 1997 . The present findings, therefore, suggest that impairment of NO production (induced by chronic L-NAME treatment), as observed in hypertension (Vanhoutte et al., 2005 (Vanhoutte et al., , 2009 , may lead to the occurrence of EDCF and hence exacerbates the initiation of vascular complications in hypertension.
In conclusion, the present study indicates that chronic NOS inhibition results in impairment of vascular relaxation and increases endothelium-dependent contractions by inducing COX-2
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